{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:14:47Z","timestamp":1788347687599,"version":"build-2803163510"},"reference-count":18,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Background: Bimekizumab, a dual IL-17A and IL-17F inhibitor, has demonstrated high efficacy in moderateto- severe psoriasis in clinical trials. However, real-world evidence in patients with moderate disease remains limited.\n\nMethods: This retrospective multicentre study evaluated the effectiveness and safety of bimekizumab over 54 weeks in adults with moderate plaque psoriasis treated across five dermatology centres in the Lazio region (Italy).\n\nResults: Fifty-nine patients initiated treatment, and 50 completed follow-up; PASI data at week 54 were available for 19 patients, whilst nail data at week 54 were available for 23 patients. Mean Psoriasis Area and Severity Index (PASI) decreased from 9.20 at baseline to 1.31 at week 4, 0.31 at week 16, 0.09 at week 24 and 0.05 at week 54. Nail involvement improved progressively, with mean Nail Psoriasis Severity Index declining from 2.96 at baseline to 0.03 at week 24, with complete clearance observed in all evaluable patients at week 54. More than 60% of patients achieved PASI90 by week 4, almost 90% reached PASI90 and approximately 88% achieved PASI100 by week 16, whilst nearly all patients attained complete clearance (PASI100) by week 54. Responses were comparable between biologic-naive and biologic-experienced patients. Adverse events occurred in 8 patients (13.6%), predominantly mild oral candidiasis, with no serious adverse events or treatment discontinuations.\n\nConclusion: These findings suggest that bimekizumab provides rapid and sustained skin clearance with favourable tolerability in patients with moderate psoriasis, supporting the consideration of early systemic treatment as a potential strategy to reduce disease burden in this population.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-real-life-effectiveness-and-safety-of-bimekizumab-in-patients-with-moderate-plaque-psoriasis-a-54-week-multicentre-study-in-the-lazio-region<\/jats:p>","DOI":"10.7573\/dic.2026-5-3","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:01:25Z","timestamp":1782838885000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Real-life effectiveness and safety of bimekizumab in patients with moderate plaque psoriasis: a 54-week multicentre study in the Lazio region"],"prefix":"10.7573","volume":"15","author":[{"given":"Francesca","family":"Feresin","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"publisher"}],"name":"Sapienza University of Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Bernardini","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"publisher"}],"name":"Sapienza University of Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Campione","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02p77k626","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Rome Tor Vergata"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Caldarola","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Gubinelli","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02b5mfy68","id-type":"ROR","asserted-by":"publisher"}],"name":"Istituto Dermopatico dell'Immacolata"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Moretta","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02b5mfy68","id-type":"ROR","asserted-by":"publisher"}],"name":"Istituto Dermopatico dell'Immacolata"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pagnanelli","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02b5mfy68","id-type":"ROR","asserted-by":"publisher"}],"name":"Istituto Dermopatico dell'Immacolata"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Giordano","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"publisher"}],"name":"Sapienza University of Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severino","family":"Persechino","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"publisher"}],"name":"Sapienza University of Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro M","family":"Falco","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Artosi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02p77k626","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Rome Tor Vergata"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zappia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"publisher"}],"name":"Sapienza University of Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"publisher"}],"name":"Sapienza University of Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Potenza","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"publisher"}],"name":"Sapienza University of Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Giovanni","family":"Richetta","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"publisher"}],"name":"Sapienza University of Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Orsini","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zhmy467","id-type":"ROR","asserted-by":"publisher"}],"name":"San Gallicano Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Dattola","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"publisher"}],"name":"Sapienza University of Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref0","unstructured":"1.\tChiricozzi A, Zhang S, Dattola A, Gabellini M, Chimenti S, Nistico SP. Role of TH17 in the pathogenesis of cutaneous inflammatory diseases. J Biol Regul Homeost Agents. 2012;26(3):313\u2013318."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tCaputo V, Strafella C, Termine A, et al. Overview of the molecular determinants contributing to the expression of psoriasis and psoriatic arthritis phenotypes. J Cell Mol Med. 2020;24(23):13554\u201313563. https:\/\/doi.org\/10.1111\/ jcmm.15742","DOI":"10.1111\/jcmm.15742"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tCampione E, Cosio T, Di Prete M, Lanna C, Dattola A, Bianchi L. Experimental pharmacological management of psoriasis. J Exp Pharmacol. 2021;13:725\u2013737. https:\/\/doi.org\/10.2147\/JEP.S265632","DOI":"10.2147\/JEP.S265632"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tOrsini D, Potestio L, Fargnoli MC, et al. Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience \u2014 IL PSO (Italian Landscape Psoriasis). Clin Exp Dermatol. 2026;51(3):418\u2013426. https:\/\/doi.org\/10.1093\/ced\/llaf486","DOI":"10.1093\/ced\/llaf486"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tLanna C, Lambiase S, Gaeta Shumak R, et al. Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology. Expert Rev Clin Pharmacol. 2022;15(10):1209\u20131224. https:\/\/doi.org\/10.1080\/17512433.2022.2130758","DOI":"10.1080\/17512433.2022.2130758"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tGargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med. 2023;10:1243843. https:\/\/doi.org\/10.3389\/ fmed.2023.1243843","DOI":"10.3389\/fmed.2023.1196966"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tOrsini D, Megna M, Assorgi C, et al. Efficacy and safety of bimekizumab in elderly patients: real-world multicenter retrospective study \u2014 IL PSO (Italian Landscape Psoriasis). J Dermatolog Treat. 2024;35(1):2393376. https:\/\/doi.org\/ 10.1080\/09546634.2024.2393376","DOI":"10.1080\/09546634.2024.2358150"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tGioacchini H, Rossi A, Esposito M, et al. Gender influence on bimekizumab response in patients with psoriasis: results of a real-world multicenter retrospective study \u2014 IL PSO (Italian Landscape PSOriasis). Dermatol Ther. 2025;15(7):1797\u20131811. https:\/\/doi.org\/10.1007\/s13555-025-01435-w","DOI":"10.1007\/s13555-025-01435-w"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tDattola A, Bernardini N, Campione E, et al. Evaluating the efficacy of bimekizumab across the different sensitive areas in moderate-to-severe psoriasis: a 52-week Italian Multicenter Real-Life Lazio Experience. Dermatol Pract Concept. 2025;15(2):4976. https:\/\/doi.org\/10.5826\/dpc.1502a4976","DOI":"10.5826\/dpc.1502a4976"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tOrsini D, Malagoli P, Balato A, et al. Bimekizumab for the treatment of plaque psoriasis with involvement of genitalia: a 16-week multicenter real-world experience \u2014 IL PSO (Italian Landscape Psoriasis). Dermatol Pract Concept. 2024;14(2):e2024052. https:\/\/doi.org\/10.5826\/dpc.1402a52","DOI":"10.5826\/dpc.1402a52"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tCampione E, Artosi F, Shumak RG, et al. Fast clinical response of bimekizumab in nail psoriasis: a retrospective multicenter 36-week real-life study. Pharmaceuticals. 2024;17(10):1378. https:\/\/doi.org\/10.3390\/ph17101378","DOI":"10.3390\/ph17101378"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tAssorgi C, Fargnoli MC, Cameli N, Dattola A, Orsini D. Successful treatment of severe acrodermatitis continua of Hallopeau (ACH) coexisting with plaque psoriasis and non-pustular palmoplantar psoriasis in an elderly patient with bimekizumab. Eur J Dermatol. 2025;35(2):146\u2013148. https:\/\/doi.org\/10.1684\/ejd.2025.4868","DOI":"10.1684\/ejd.2025.4868"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tCaldarola G, Dattola A, Bernardini N, et al. Effectiveness of bimekizumab in psoriatic arthritis: a multicenter real-life study with clinical and ultrasound evaluation in the Lazio region, Italy. Int J Dermatol. 2025;64(11):2038\u20132044. https:\/\/doi.org\/10.1111\/ijd.17927","DOI":"10.1111\/ijd.17927"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tMegna M, Orsini D, Assorgi C, et al. The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience \u2014 IL PSO (Italian Landscape Psoriasis). Clin Exp Dermatol. 2025;50(4):858\u2013859. https:\/\/doi.org\/10.1093\/ced\/llae400","DOI":"10.1093\/ced\/llaf175"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tCaldarola G, De Luca E, Amato S, et al. Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy. Clin Exp Dermatol. 2025;50(11):2185\u20132191. https:\/\/doi.org\/10.1093\/ced\/llaf271","DOI":"10.1093\/ced\/llaf271"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tEsposito M, Gisondi P, Assorgi C, et al. Super responder profile under bimekizumab treatment in moderate-to-severe psoriasis: a short term real-life observation \u2014 IL PSO (Italian Landscape Psoriasis). Clin Drug Investig. 2025;45(6):309\u2013315. https:\/\/doi.org\/10.1007\/s40261-025-01440-z","DOI":"10.1007\/s40261-025-01440-z"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tBernardini N, Dattola A, Caldarola G, et al. Rapid response on facial psoriasis to bimekizumab: case series. Drugs Context. 2024;13:2024-1-4. https:\/\/doi.org\/10.7573\/dic.2024-1-4","DOI":"10.7573\/dic.2024-1-4"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tSasso FP, Dattola A, Righetta AG, Pellacani G. Super long-term response in a psoriatic patient after discontinuation of bimekizumab: is there a new possibility for the management of chronic plaque psoriasis? Ital J Dermatol Venerol. 2024;159(5):582\u2013583. https:\/\/doi.org\/10.23736\/S2784-8671.24.07863-0","DOI":"10.23736\/S2784-8671.24.07863-0"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/07\/dic.2026-5-3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:32:50Z","timestamp":1788345170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/real-life-effectiveness-and-safety-of-bimekizumab-in-patients-with-moderate-plaque-psoriasis-a-54-week-multicentre-study-in-the-lazio-region"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-5-3","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"dic.2026-5-3"}}